Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

COVID-19 Vaccines in Clinical Trials and their Mode of Action for Immunity against the Virus

Author(s): Shima Tavakol*, Mo S. Alavijeh and Alexander M. Seifalian*

Volume 27, Issue 13, 2021

Published on: 23 October, 2020

Page: [1553 - 1563] Pages: 11

DOI: 10.2174/1381612826666201023143956

Price: $65

Abstract

For nearly two decades, coronaviruses have caused many health and economic problems, while no effective commercial vaccine has yet been developed. It is worth mentioning that despite some mutations and recombination in SARS-CoV-2, its genotype is very close to the original strain from Wuhan, China. Therefore, the development of an effective vaccine would be promising. It might be hypothesized that BCG vaccination is performed in high-risk populations before the commercialization of an effective SARS-CoV-2 vaccine. However, the development of an effective vaccine without considering the adverse immune reactions derived from antibody-dependent or cell-based immune enhancement may threaten vaccinated people's lives and long-term side effects must be considered. To this end, targeting of the receptor-binding domain (RBD) in spike and not whole spike, glycolization of FC receptors, PD-1 blockers, CPPs, etc., are promising. Therefore, the subunit vaccines or RNA vaccines that encode the RBP segment of the spike are of interest. To enhance the vaccine efficacy, its co-delivery with an adjuvant has been recommended. Nanoparticles modulate immune response with higher efficiency than the soluble form of antigens and can be functionalized with the positively charged moieties and ligands of targeted cells, such as dendritic cells, to increase cellular uptake of the antigens and their presentation on the surface of immune cells. This research aimed to discuss the COVID-19 vaccines entering the clinical trial and their mode of action effective immunity against the virus and discusses their advantages compared to each other.

Keywords: SARS-CoV-2, COVID-19, vaccine, ADE, immune enhancement, spike, coronavirus, clinical.

« Previous Next »
[1]
Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses 2020; 12(2): 135.
[http://dx.doi.org/10.3390/v12020135] [PMID: 31991541]
[2]
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-280.e8.
[http://dx.doi.org/10.1016/j.cell.2020.02.052] [PMID: 32142651]
[3]
Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov 2020; 6: 14.
[http://dx.doi.org/10.1038/s41421-020-0153-3] [PMID: 32194980]
[4]
Chan JF-W, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020; 9(1): 221-36.
[http://dx.doi.org/10.1080/22221751.2020.1719902] [PMID: 31987001]
[5]
Cascella M, Rajnik Michael , Cuomo Arturo, Dulebohn Scott C, R. D. Napoli. Features, Evaluation and Treatment Coronavirus (COVID-19). Treasure Island, FL: StatPearls Publishing 2010.
[6]
Sexton NR, Smith EC, Blanc H, Vignuzzi M, Peersen OB, Denison MR. Homology-based identification of a mutation in the coronavirus RNA-dependent RNA polymerase that confers resistance to multiple mutagens. J Virol 2016; 90(16): 7415-28.
[http://dx.doi.org/10.1128/JVI.00080-16] [PMID: 27279608]
[7]
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020; 19(3): 149-50.
[http://dx.doi.org/10.1038/d41573-020-00016-0] [PMID: 32127666]
[8]
Brooks G, Carroll K, Butel J, Morse S, Mietzner T. Adelberg Medical Microbiology Placebo doo. Jawetz, Melnick 2015.
[9]
Biswas A, Bhattacharjee U, Chakrabarti AK, Tewari DN, Banu H, Dutta S. Emergence of Novel Coronavirus and COVID-19: whether to stay or die out? Crit Rev Microbiol 2020; 46(2): 182-93.
[http://dx.doi.org/10.1080/1040841X.2020.1739001] [PMID: 32282268]
[10]
Yao H-P, Lu X, Chen Q, et al. Patient-derived mutations impact pathogenicity of SARS-CoV-2. Cell Discov 2020; 6: 76.
[11]
James H. Strauss. Viruses and human diseases. 2nd Ed. Academic Press 2008; pp. 1-33.
[http://dx.doi.org/10.1016/C2009-0-02104-7]
[12]
Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol 2010; 84(24): 12658-64.
[http://dx.doi.org/10.1128/JVI.01542-10] [PMID: 20926566]
[13]
Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher T. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol 2011; 85(2): 873-82.
[http://dx.doi.org/10.1128/JVI.02062-10] [PMID: 21068237]
[14]
Heald-Sargent T, Gallagher T. Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses 2012; 4(4): 557-80.
[http://dx.doi.org/10.3390/v4040557] [PMID: 22590686]
[15]
Kumar N, Sood D, van der Spek PJ, Sharma HS, Chandra R. Molecular binding mechanism and pharmacology comparative analysis of noscapine for repurposing against SARS-CoV-2 protease. J Proteome Res 2020.
[http://dx.doi.org/10.1021/acs.jproteome.0c00367] [PMID: 32786685]
[16]
Wu D, Koganti R, Lambe UP, Yadavalli T, Nandi SS, Shukla D. Vaccines and therapies in development for SARS-CoV-2 infections. J Clin Med 2020; 9(6): 1885.
[http://dx.doi.org/10.3390/jcm9061885] [PMID: 32560227]
[17]
Iwata-Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, Takeda M, Nagata N. TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J Virol 2019; 93(6): e01815-8.
[http://dx.doi.org/10.1128/JVI.01815-18] [PMID: 30626688]
[18]
Shirato K, Kawase M, Matsuyama S. Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry. Virology 2018; 517: 9-15.
[http://dx.doi.org/10.1016/j.virol.2017.11.012] [PMID: 29217279]
[19]
Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res 2015; 116: 76-84.
[http://dx.doi.org/10.1016/j.antiviral.2015.01.011] [PMID: 25666761]
[20]
Menachery VD, Dinnon KH III, Yount BL Jr, et al. Trypsin treatment unlocks barrier for zoonotic bat coronavirus infection. J Virol 2020; 94(5): 94.
[PMID: 31801868]
[21]
Korber B, Fischer WM, Gnanakaran S, et al. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS- CoV-2. bioRxiv 2020.
[22]
WHO. Immunity Passports" in the Context of Covid-19. Available from: https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19
[23]
Piechotta V. Plasma from people who have recovered from COVID-19 to treat individuals with COVID-19. Cochrane Database Syst Rev 2020.
[24]
Ries J. COVID-19 Will Mutate -What That Means for a Vaccine. Healthline. Available from: https://www.healthline.com/health-news/what-to-know-about-mutation-and-covid-19
[25]
Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis 2016; 49: 129-33.
[http://dx.doi.org/10.1016/j.ijid.2016.06.015] [PMID: 27352628]
[26]
O’Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7(5): 353-64.
[http://dx.doi.org/10.1038/nri2079] [PMID: 17457343]
[27]
Felsenstein S, Herbert JA, McNamara PS, Hedrich M. C. COVID-19: Immunology and treatment options. Clin Immunol 2020; 215.
[28]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[29]
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020; 20(6): 363-74.
[http://dx.doi.org/10.1038/s41577-020-0311-8] [PMID: 32346093]
[30]
Mubarak A, Alturaiki W, Hemida MG. Middle east respiratory syndrome coronavirus (MERS-CoV): infection, immunological response, and vaccine development. J Immunol Res 2019; 2019: 6491738.
[http://dx.doi.org/10.1155/2019/6491738] [PMID: 31089478]
[31]
Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv 2020.
[http://dx.doi.org/10.2139/ssrn.3566211]
[32]
Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol 2020; 94(5): 94.
[PMID: 31826992]
[33]
Deming D, Sheahan T, Heise M, et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med 2006; 3(12): e525.
[http://dx.doi.org/10.1371/journal.pmed.0030525] [PMID: 17194199]
[34]
Yasui F, Kai C, Kitabatake M, et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol 2008; 181(9): 6337-48.
[http://dx.doi.org/10.4049/jimmunol.181.9.6337] [PMID: 18941225]
[35]
Zhu Z, Chakraborti S, He Y, et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci USA 2007; 104(29): 12123-8.
[http://dx.doi.org/10.1073/pnas.0701000104] [PMID: 17620608]
[36]
Wang C, Li W, Drabek D, et al. A human monoclonal 1 antibody blocking SARS-CoV-2 infection. bioRxiv 2020; 11(1): 2251.
[http://dx.doi.org/10.1038/s41467-020-16256-y]
[37]
Genomic epidemiology of novel coronavirus - Global subsampling. GISAID 2020.
[38]
Moshiri N. Coronavirus seems to mutate much slower than seasonal flu.Livescience 2020.
[39]
Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008; (2): CD004879.
[http://dx.doi.org/10.1002/14651858.CD004879.pub3] [PMID: 18425905]
[40]
Drexler JF, Gloza-Rausch F, Glende J, et al. Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences. J Virol 2010; 84(21): 11336-49.
[http://dx.doi.org/10.1128/JVI.00650-10] [PMID: 20686038]
[41]
Baric RS, Yount B, Hensley L, Peel SA, Chen W. Episodic evolution mediates interspecies transfer of a murine coronavirus. J Virol 1997; 71(3): 1946-55.
[http://dx.doi.org/10.1128/JVI.71.3.1946-1955.1997] [PMID: 9032326]
[42]
Health J H B S o P. Sars-Cov-2 Genetics Center for Health Security. 2020.
[43]
Martin JE, Louder MK, Holman LA, et al. VRC 301 Study Team. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 2008; 26(50): 6338-43.
[http://dx.doi.org/10.1016/j.vaccine.2008.09.026] [PMID: 18824060]
[44]
Lin JT, Zhang JS, Su N, et al. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther (Lond) 2007; 12(7): 1107-13.
[PMID: 18018769]
[45]
Roper RL, Rehm KE. SARS vaccines: where are we? Expert Rev Vaccines 2009; 8(7): 887-98.
[http://dx.doi.org/10.1586/erv.09.43] [PMID: 19538115]
[46]
Bolles M, Deming D, Long K, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol 2011; 85(23): 12201-15.
[http://dx.doi.org/10.1128/JVI.06048-11] [PMID: 21937658]
[47]
Wang Q, Zhang L, Kuwahara K, et al. Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. ACS Infect Dis 2016; 2(5): 361-76.
[http://dx.doi.org/10.1021/acsinfecdis.6b00006] [PMID: 27627203]
[48]
Tseng C-T, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 2012; 7(4): e35421.
[http://dx.doi.org/10.1371/journal.pone.0035421] [PMID: 22536382]
[49]
Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 2004; 78(22): 12672-6.
[http://dx.doi.org/10.1128/JVI.78.22.12672-12676.2004] [PMID: 15507655]
[50]
Houser KV, Broadbent AJ, Gretebeck L, et al. Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. PLoS Pathog 2017; 13(8): e1006565.
[http://dx.doi.org/10.1371/journal.ppat.1006565] [PMID: 28817732]
[51]
Sepkowitz K. When Can a Covid-19 Vaccine Really Be Ready? CNN. New York 2020. Available from: https://edition.cnn.com/2020/05/04/opinions/when-can-a-covid-19-vaccine-really-be-ready-sepkowitz/index.html
[52]
Peeples L. News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proc Natl Acad Sci USA 2020; 117(15): 8218-21.
[http://dx.doi.org/10.1073/pnas.2005456117] [PMID: 32229574]
[53]
Jando J, Camargo SMR, Herzog B, Verrey F. Expression and regulation of the neutral amino acid transporter B0AT1 in rat small intestine. PLoS One 2017; 12(9): e0184845.
[http://dx.doi.org/10.1371/journal.pone.0184845] [PMID: 28915252]
[54]
WHO. DRAFT landscape of COVID-19 candidate vaccines -29. Available from: https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19
[55]
Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity 2020; 52(4): 583-9.
[http://dx.doi.org/10.1016/j.immuni.2020.03.007] [PMID: 32259480]
[56]
Le TT, Cramer JP, Chen R, Mayhew S. Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; 19(10): 667-8.
[http://dx.doi.org/10.1038/d41573-020-00151-8] [PMID: 32887942]
[57]
Miller A, Reavdelar MJ, Reavdelar , et al. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study medRxiv 2020.
[58]
Kim SS, Shen S, Miyauchi S, et al. B-cells improve overall survival in HPV-associated squamous cell carcinomas and are activated by radiation and PD-1 blockade. Clin Cancer Res 2020; 26(13): 3345-59.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-3211] [PMID: 32193227]
[59]
Kaneko Y, Nimmerjahn F, Ravetch J V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation science 2006; 313: 670-3.
[60]
Tsai TF. Fluad®-MF59®-adjuvanted influenza vaccine in older adults. Infect Chemother 2013; 45(2): 159-74.
[http://dx.doi.org/10.3947/ic.2013.45.2.159] [PMID: 24265964]
[61]
DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine 2013; 31(6): 861-6.
[http://dx.doi.org/10.1016/j.vaccine.2012.12.013] [PMID: 23261045]
[62]
Zhu M, Wang R, Nie G. Applications of nanomaterials as vaccine adjuvants. Hum Vaccin Immunother 2014; 10(9): 2761-74.
[http://dx.doi.org/10.4161/hv.29589] [PMID: 25483497]
[63]
Carty M, Bowie AG. Recent insights into the role of Toll-like receptors in viral infection. Clin Exp Immunol 2010; 161(3): 397-406.
[http://dx.doi.org/10.1111/j.1365-2249.2010.04196.x] [PMID: 20560984]
[64]
Lester SN, Li K. SN. Toll-like receptors in antiviral innate immunity. J Mol Biol 2014; 426(6): 1246-64.
[http://dx.doi.org/10.1016/j.jmb.2013.11.024] [PMID: 24316048]
[65]
Olejnik J. Adam J. Hume & Mühlberger, E. Toll-like receptor 4 in acute viral infection: Too much of a good thing. PLoS Pathog 2018; 14.
[66]
Patel Mira C, et al. Novel drugs targeting toll-like receptors for antiviral therapy future virol 2014; 9: 811-29.
[67]
The latest in the COVID-19 vaccine race 2020.

Rights & Permissions Print Cite
Article Metrics
48
2
© 2024 Bentham Science Publishers | Privacy Policy